Skip to content

Commercial Consolidation in Spatial Omics

The spatial omics instrument landscape is undergoing rapid consolidation. Between 2023 and 2024, three major events reshaped the commercial field: Bruker acquired NanoString, 10x Genomics acquired Vizgen, and Ionpath shut down. The result is a market with fewer independent vendors, larger integrated platforms, and increasing concerns about vendor lock-in.

The consolidation events

10x Genomics acquires Vizgen (2024)

10x Genomics, the dominant player in sequencing-based spatial transcriptomics (Visium, Xenium), acquired Vizgen in 2024. Vizgen developed the MERSCOPE platform, which commercialized MERFISH -- one of the two leading imaging-based spatial transcriptomics technologies.

What this means:

  • 10x now controls both sequencing-based (Visium, Visium HD) and imaging-based (Xenium, MERSCOPE/MERFISH) spatial transcriptomics
  • The two leading imaging-based platforms (Xenium and MERSCOPE) are now under one roof
  • MERFISH, originally an academic technology developed by Xiaowei Zhuang's lab at Harvard, moves further into the proprietary sphere
  • Existing MERSCOPE users face uncertainty about long-term platform support and reagent availability

Bruker acquires NanoString (2023)

Bruker, a diversified instrumentation company, acquired NanoString Technologies in 2023. NanoString developed the GeoMx Digital Spatial Profiler and the CosMx Spatial Molecular Imager.

What this means:

  • GeoMx (region-of-interest spatial profiling) and CosMx (single-cell spatial transcriptomics) now operate under Bruker's life sciences division
  • NanoString's financial difficulties prior to acquisition had raised concerns about platform viability; Bruker's acquisition provides stability
  • CosMx remains the primary competitor to Xenium in the commercial single-cell spatial transcriptomics market
  • Integration into Bruker's broader instrumentation portfolio could accelerate multi-modal workflows (e.g., combining CosMx with mass spectrometry imaging)

Ionpath shuts down (2024)

Ionpath, the company commercializing Multiplexed Ion Beam Imaging (MIBI-TOF) for spatial proteomics, ceased operations in 2024.

What this means:

  • MIBI-TOF, a technology developed by Michael Angelo's lab at Stanford, loses its commercial platform
  • Existing MIBI-TOF instruments become unsupported; reagent supply chains are disrupted
  • Researchers with MIBI data face long-term data format and reproducibility challenges
  • The spatial proteomics market consolidates around Imaging Mass Cytometry (Standard BioTools/Fluidigm), CODEX/PhenoCycler (Akoya Biosciences), and antibody-based approaches

The current landscape

Vendor Platforms Technology type Market position
10x Genomics Visium, Visium HD, Xenium, MERSCOPE Sequencing-based + imaging-based transcriptomics Dominant, broadest portfolio
Bruker (NanoString) CosMx, GeoMx Imaging-based transcriptomics + ROI profiling Strong second, growing
Akoya Biosciences PhenoCycler (CODEX), PhenoImager Spatial proteomics (cyclic immunofluorescence) Leading spatial proteomics
Standard BioTools Imaging Mass Cytometry (IMC) Spatial proteomics (mass cytometry) Established, niche
BGI/STOmics Stereo-seq Sequencing-based transcriptomics Strong in Asia, growing globally
Resolve Biosciences Molecular Cartography Imaging-based transcriptomics Smaller, European market
Curio Bioscience Slide-seq (Curio Seeker) Sequencing-based transcriptomics Niche, bead-based

Implications for researchers

Fewer choices, clearer defaults

Consolidation simplifies platform selection for new adopters. The choice for spatial transcriptomics is increasingly binary: 10x (Visium/Xenium) for the broadest ecosystem and most third-party tool support, or Bruker (CosMx) for an alternative with different technical strengths (larger gene panels, FFPE optimization).

Vendor lock-in risks

As fewer vendors control more of the technology stack, researchers face increasing lock-in through:

  • Proprietary data formats. Each vendor uses custom file formats that require vendor software for initial processing. While open-source converters exist, they lag behind vendor format updates.
  • Proprietary analysis software. 10x's Loupe Browser, NanoString's AtoMx, and Akoya's InForm/HALO provide vendor-curated analysis workflows. These are convenient but create dependency.
  • Reagent ecosystems. Gene panels, probe sets, and antibody conjugates are vendor-specific and often proprietary. Switching platforms means redesigning the entire experimental panel.
  • Instrument-software coupling. Raw data processing (e.g., Space Ranger for Visium, Xenium Ranger) is tightly coupled to vendor instruments. Open-source alternatives (STARsolo, Baysor) exist but are not always feature-complete.

The vendor lock-in trap

Choosing a spatial platform is a multi-year commitment. The instrument cost ($200k--$800k), reagent contracts, and workflow development create high switching costs. Platform discontinuation (as with Ionpath/MIBI) can strand years of investment.

Data format fragmentation

Each consolidation event risks creating larger but still incompatible data ecosystems:

  • 10x formats: Space Ranger H5, Xenium cell feature matrix, MERSCOPE output
  • Bruker/NanoString formats: CosMx flat files, GeoMx DSP exports
  • Akoya formats: CODEX/PhenoCycler QPTIFF

The scverse ecosystem (AnnData, SpatialData) provides the most promising path toward format-agnostic analysis, with readers for most major formats. But conversion is imperfect, and vendor-specific metadata is often lost in translation.

Open-source as counterbalance

Academic open-source tools serve as a critical counterbalance to commercial consolidation. Key projects:

Project Role Significance
SpatialData (scverse) Universal data container Technology-agnostic data representation reduces vendor lock-in
Squidpy Spatial analysis framework Vendor-independent analysis workflows
Baysor Cell segmentation Open alternative to vendor segmentation pipelines
STARsolo Raw data processing Open alternative to Space Ranger
napari Visualization Open alternative to vendor visualization tools
Giotto Analysis framework (R) Comprehensive open-source alternative

These tools cannot replace vendor instruments, but they reduce dependency on vendor software for downstream analysis. Investing in open-source spatial analysis tools is both a scientific and a strategic decision.

BGI/STOmics: the non-Western alternative

BGI Genomics, through its STOmics division, offers Stereo-seq -- a sequencing-based spatial technology with nanometer resolution across large tissue areas. Stereo-seq has several distinctive characteristics:

  • Achieves the highest spatial resolution of any sequencing-based method
  • Has produced the largest published spatial datasets (mouse embryo atlas with billions of reads)
  • Is widely used in China and increasingly in Europe, but has limited adoption in North America
  • Uses its own data ecosystem (STOmicsDB, SAW pipeline) with growing but incomplete interoperability with Western tools
  • Faces geopolitical headwinds that may limit adoption in some research environments

As 10x and Bruker consolidate the Western market, BGI/STOmics represents an independent alternative that may grow in importance globally.

What to watch

Will 10x unify Xenium and MERSCOPE? The two platforms have overlapping capabilities. 10x may maintain both, merge them, or phase out MERSCOPE in favor of Xenium. This decision will significantly affect existing MERSCOPE users.

Will Bruker invest in CosMx? NanoString's acquisition by Bruker provides financial stability, but Bruker's commitment to continued CosMx development and market competition with 10x will determine whether a viable second option persists.

Will open-source alternatives mature? Projects like SpatialData, Squidpy, and napari are the best insurance against vendor lock-in. Their continued development depends on academic funding and community contributions -- both of which are fragile.

Will new entrants emerge? The spatial omics market is large and growing. New technologies (expansion microscopy, in situ sequencing variants, novel imaging modalities) could produce new commercial entrants, countering consolidation.

Further reading